<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liposomal bupivacaine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liposomal bupivacaine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Liposomal bupivacaine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="17057" href="/d/html/17057.html" rel="external">see "Liposomal bupivacaine: Drug information"</a> and <a class="drug drug_patient" data-topicid="83361" href="/d/html/83361.html" rel="external">see "Liposomal bupivacaine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F14187699"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Exparel</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F22800200"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Nonopioid</span></li></ul></div>
<div class="block dop drugH1Div" id="F55771984"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;">
<b>Note:</b> Bupivacaine (liposomal) is not bioequivalent to bupivacaine hydrochloride; dosing conversion from bupivacaine hydrochloride to bupivacaine (liposomal) or vice versa is not possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c92ce236-f868-437a-afd0-227355dfb507">Local analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local analgesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years: Local infiltration: 4 mg/kg administered once; maximum dose: 266 mg/dose (20 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Local infiltration: Single dose: Dose is based on size of surgical site, volume required to cover the area, and individual patient factors; maximum dose: 266 mg/dose (20 mL).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F55771985"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; renal impairment may reduce bupivacaine elimination, increasing systemic exposure and the risk of adverse effects or toxicities; use with caution and monitor closely.</p></div>
<div class="block dohp drugH1Div" id="F55771986"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor closely; severe impairment may reduce bupivacaine metabolism, increasing systemic exposure and the risk of adverse effects or toxicities.</p></div>
<div class="block doa drugH1Div" id="F14080900"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="17057" href="/d/html/17057.html" rel="external">see "Liposomal bupivacaine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Bupivacaine (liposomal) is not bioequivalent to bupivacaine hydrochloride; dosing conversion from bupivacaine hydrochloride to bupivacaine (liposomal) or vice versa is not possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="526d52c3-3957-4913-8db7-be6cf2e9a160">Analgesia, postsurgical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, postsurgical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Local anesthesia: </b>Infiltration: Single dose: Dose is based on size of surgical site, volume required to cover the area, and individual patient factors (maximum dose: 266 mg [20 mL]). General dosage guidance for bunionectomy and hemorrhoidectomy provided below:</p>
<p style="text-indent:-2em;margin-left:6em;">Bunionectomy: 7 mL of undiluted bupivacaine (liposomal) infiltrated into the tissues surrounding the osteotomy and 1 mL of undiluted bupivacaine (liposomal) infiltrated into the subcutaneous tissue of the surgical site (total dose = 106 mg [8 mL])</p>
<p style="text-indent:-2em;margin-left:6em;">Hemorrhoidectomy: 30 mL of diluted bupivacaine (liposomal) (20 mL diluted with 10 mL NS) divided and infiltrated as 6 injections of 5 mL each (total dose = 266 mg [20 mL]) around the anal sphincter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Regional analgesia: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Adductor canal block: Single dose: Total knee arthroplasty: 133 mg (10 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Interscalene brachial plexus nerve block: Single dose: Total shoulder arthroplasty or rotator cuff repair: 133 mg (10 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Sciatic nerve block in the popliteal fossa: Single dose: Bunionectomy: 133 mg (10 mL).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50989973"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; renal impairment may reduce bupivacaine elimination increasing systemic exposure and the risk of adverse effects or toxicities; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987308"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; severe impairment may reduce bupivacaine metabolism increasing systemic exposure and the risk of adverse effects or toxicities.</p></div>
<div class="block adr drugH1Div" id="F14080872"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (2% to 22%), nausea (2% to 40%), vomiting (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Motor dysfunction (12% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (&lt;2%), bradycardia (1% to 2%), cardiac arrhythmia (&lt;2%), deep vein thrombosis (&lt;2%), edema (&lt;2%), first degree atrioventricular block (&lt;2%), hypertension (&lt;10%), hypotension (7%), left bundle branch block (&lt;2%), orthostatic hypotension (&lt;2%), oxygen saturation decreased (&lt;2%), palpitations (&lt;2%), peripheral edema (2% to 3%), presyncope (&lt;2%), prolonged QT interval on ECG (&lt;2%), right bundle branch block (&lt;2%), sinus bradycardia (&lt;2%), sinus tachycardia (2% to 3%), supraventricular extrasystole (&lt;2%), syncope (2%), tachycardia (3% to 4%), ventricular premature contractions (&lt;2%), ventricular tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (&lt;2%), diaphoresis (&lt;2%), erythema of skin (&lt;2%), hyperhidrosis (5%), increased wound secretion (&lt;2%), pallor (&lt;2%), pruritic rash (&lt;2%), pruritus (3%), skin blister (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (7%), hiccups (1% to 2%), oral hypoesthesia (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (&lt;2%), urinary incontinence (&lt;2%), urinary retention (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (6%, including acute posthemorrhagic anemia), hematoma (&lt;2%), leukocytosis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (4%), increased serum alanine aminotransferase (1%), increased serum aspartate aminotransferase (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Fixed drug eruption (&lt;2%), hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (&lt;2%), anxiety (3%), chills (&lt;2%), confusion (5%), delirium (&lt;2%), depression (&lt;2%), dizziness (6%; includes postural dizziness), drowsiness (2% to 5%), fatigue (5%), feeling hot (2%), headache (4% to 8%), hyperthermia (&lt;2%), hypoesthesia (2% to 4%), impaired mobility (decreased: 2%), insomnia (2% to 10%), lethargy (1%), myasthenia (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), restlessness (&lt;2%), sedated state (&lt;2%), sensation disorder (sensory loss: 2%), sensation of cold (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), asthenia (&lt;2%), back pain (&lt;10%), joint swelling (&lt;2%), laryngospasm (&lt;2%), muscle spasm (&lt;10%), muscle twitching (8%), musculoskeletal pain (&lt;2%), neck pain (&lt;2%), tremor (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&lt;2%), decreased visual acuity (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (&lt;2%), atelectasis (&lt;2%), cough (&lt;2%), dyspnea (&lt;2%), hypoxia (1% to 2%), pneumonia (&lt;2%), pulmonary infection (&lt;2%), pulmonary infiltrates (&lt;2%), respiratory depression (&lt;2%), respiratory failure (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Paralysis, seizure</p></div>
<div class="block coi drugH1Div" id="F14080834"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Obstetrical paracervical block anesthesia</p></div>
<div class="block war drugH1Div" id="F14080835"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: CNS effects (including excitation and/or depression) may occur, possibly leading to convulsions, unconsciousness, and/or respiratory arrest; may be related to total dose administered, route of administration, and physical status of patient; monitor for CNS-related changes or alterations in consciousness after each injection. Additionally, use of local anesthetics have been associated with neurologic effects following infiltration of soft tissue (persistent anesthesia, paresthesia weakness, paralysis), which may be irreversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, twitching, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Sensory and/or motor loss is temporary and varies and may last up to 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular toxicity: Serious and fatal cardiovascular system reactions (eg, decreased cardiac output and arterial blood pressure, atrioventricular block, ventricular arrhythmias, cardiac arrest) may occur with toxic concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Allergic-type reactions (eg, angioneurotic edema [including laryngeal edema], dizziness, elevated temperature, excessive sweating, nausea, syncope, tachycardia, pruritus, erythema, sneezing, urticaria, vomiting) and possibly anaphylactoid-like symptoms (including severe hypotension) have been reported (rare); cross-sensitivity among amide-type local anesthetics has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is not an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have been reported with local anesthetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; patients with impaired cardiovascular function are less able to compensate for functional changes associated with AV conduction prolongation produced by bupivacaine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; patients with severe impairment may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid intravascular, epidural, intrathecal, and intra-articular nerve block injections. Not indicated for preincisional or preprocedural locoregional anesthetic techniques that require deep and complete sensory block. Do not administer other local anesthetics or other formulations of bupivacaine within 96 hours following bupivacaine (liposomal) administration. Aspiration should be performed frequently prior to and during administration; the needle should be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Bupivacaine hydrochloride is not bioequivalent to bupivacaine (liposomal); dosing conversion from bupivacaine hydrochloride to bupivacaine (liposomal) and vice versa is not possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F14080946"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exparel: 1.3% (10 mL, 20 mL)</p></div>
<div class="block geq drugH1Div" id="F14080936"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322920"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Exparel Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.3% (per mL): $27.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F55771988"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Local infiltration: Administer undiluted or diluted. Inject slowly (1 to 2 mL per injection) into the surgical site using a ≥25-gauge needle with frequent aspiration prior to and during administration; do not filter. Do not administer epidurally, intrathecally, intravascularly, or intra-articularly. Do not allow bupivacaine (liposomal) to come into contact with antiseptics (eg, povidone-iodine) in solution; when a topical antiseptic is applied, allow site to dry prior to injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Nonbupivacaine-based local anesthetics may cause an immediate release of bupivacaine (liposomal) if administered together locally; therefore, <b>bupivacaine (liposomal)</b> should be administered no sooner than 20 minutes after injection of <b>lidocaine</b>. Do not administer other local anesthetics or other formulations of bupivacaine within 96 hours following bupivacaine (liposomal) administration; bupivacaine hydrochloride may be administered simultaneously in the same syringe or injected immediately before bupivacaine (liposomal) as long as the milligram ratio of bupivacaine hydrochloride to bupivacaine (liposomal) does not exceed 1:2.</p></div>
<div class="block adm drugH1Div" id="F14080903"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Do not heat or autoclave prior to administration. Administer undiluted or diluted. Inject slowly (1 to 2 mL per injection) into the surgical site using a ≥25-gauge needle with frequent aspiration prior to and during administration; do not filter. Do not administer epidurally, intrathecally, intravascularly, or intra-articularly. Do not allow bupivacaine (liposomal) to come into contact with antiseptics (eg, povidone iodine) in solution; when a topical antiseptic is applied, allow site to dry prior to injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Non–bupivacaine-based local anesthetics may cause an immediate release of bupivacaine (liposomal) if administered together locally; therefore, <b>
<span style="text-decoration: underline">bupivacaine</span></b> should be administered no sooner than 20 minutes after injection of <b>
<span style="text-decoration: underline">lidocaine</span></b>. Do not administer other local anesthetics or other formulations of bupivacaine within 96 hours following bupivacaine (liposomal) administration; bupivacaine hydrochloride may be administered simultaneously in the same syringe or injected immediately before bupivacaine (liposomal) as long as the milligram ratio of bupivacaine hydrochloride to bupivacaine (liposomal) does not exceed 1:2.</p>
<p style="text-indent:-2em;margin-left:2em;">Adductor canal block: Manufacturer's labeling recommends mixing 10 mL (133 mg) of bupivacaine (liposomal) with 10 mL (50 mg) of 0.5% bupivacaine (total volume: 20 mL).</p></div>
<div class="block sts drugH1Div" id="F14080881"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); may also store at 20°C to 25°C (68°F to 77°F) for up to 30 days (do not re-refrigerate); do not heat or autoclave vials before use. Following withdrawal from the vial, store at 20°C to 25°C (68°F to 77°F) up to 4 hours prior to administration. Diluted suspensions must be used within 4 hours of preparation. Do not freeze or expose to high temperature (&gt;40°C [104°F]) for an extended period of time or administer if suspected of being frozen or exposed to high temperatures. Discard any unused portion.</p></div>
<div class="block usep drugH1Div" id="F53570980"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Single-dose infiltration to produce postsurgical local analgesia (FDA approved in ages ≥6 years and adults); interscalene brachial plexus nerve block to produce postsurgical regional analgesia (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F13321183"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bupivacaine may be confused with mepivacaine, ropivacaine </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bupivacaine liposomal may be confused with conventional bupivacaine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bupivacaine liposomal may be confused with propofol due to similar white, milky appearance.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46059031"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F46059028"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: May enhance the adverse/toxic effect of BUPivacaine (Liposomal). Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): May enhance the adverse/toxic effect of BUPivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with lidocaine. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine. Lidocaine may be administered 96 hours or more after liposomal bupivacaine administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the adverse/toxic effect of BUPivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F14080832"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bupivacaine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Following use of the nonliposomal formulation, small amounts of bupivacaine can be found in the maternal plasma, potentially causing varying degrees of maternal, fetal, and neonatal toxicity involving the CNS, peripheral vascular tone, and cardiac function.</p>
<p style="text-indent:0em;margin-top:2em;">Liposomal bupivacaine is approved for postsurgical local analgesia; studies have evaluated its use for intra-incisional blocks at the time of cesarean delivery to decrease postoperative pain (Parikh 2019; Prabhu 2018). Use of bupivacaine in obstetrical paracervical block anesthesia is contraindicated (may cause fetal bradycardia and death).</p></div>
<div class="block mopp drugH1Div" id="F53570978"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiovascular and respiratory (adequacy of ventilation) vital signs, state of consciousness, signs of CNS toxicity, pain relief.</p></div>
<div class="block pha drugH1Div" id="F14080885"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.</p></div>
<div class="block phk drugH1Div" id="F14080887"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Rapid (Hu 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Local: Up to 72 hours (Hu 2013); Systemic: Plasma levels can persist for 96 hours after local administration, 120 hours after interscalene brachial plexus nerve block, and 168 hours after adductor canal block or sciatic nerve block in the popliteal fossa.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Systemic absorption varies; dependent on dose, route of administration, and vascularity of administration site</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via conjugation; major metabolite pipecoloxylidine (PPX; inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 13 to 34 hours (Hu 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Within 1 hour (initial peak); 12 to 36 hours (second peak) (Hu 2013)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~6% unchanged)</p></div>
<div class="block phksp drugH1Div" id="F51154042"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Renal impairment may reduce bupivacaine elimination increasing systemic exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Severe impairment may reduce bupivacaine metabolism increasing systemic exposure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58208597"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bloqueina</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Exparel liposomal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Anecain</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists' (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al, “Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,” <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exparel.1">
<a name="Exparel.1"></a>Exparel (bupivacaine liposomal) [prescribing information]. San Diego, CA: Pacira Pharmaceuticals Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21842428">
<a name="21842428"></a>Golf M, Daniels SE, and Onel E, "A Phase 3, Randomized, Placebo-Controlled Trial of Depofoam® Bupivacaine (Extended-Release Bupivacaine Local Analgesic) in Bunionectomy," <i>Adv Ther</i>, 2011, 28(9):776-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/21842428/pubmed" id="21842428" target="_blank">21842428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22067185">
<a name="22067185"></a>Gorfine SR, Onel E, Patou G, et al, "Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial," <i>Dis Colon Rectum</i>, 2011, 54(12):1552-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/22067185/pubmed" id="22067185" target="_blank">22067185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23229686">
<a name="23229686"></a>Hu D, Onel E, Singla N, Kramer WG, Hadzic A. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. <i>Clin Drug Investig</i>. 2013;33(2):109-115. doi: 10.1007/s40261-012-0043-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/23229686/pubmed" id="23229686" target="_blank">23229686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32541292">
<a name="32541292"></a>Mustafa HJ, Wong HL, Al-Kofahi M, Schaefer M, Karanam A, Todd MM. Bupivacaine pharmacokinetics and breast milk excretion of liposomal bupivacaine administered after cesarean birth. <i>Obstet Gynecol</i>. 2020;136(1):70-76. doi:10.1097/AOG.0000000000003886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/32541292/pubmed" id="32541292" target="_blank">32541292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22189574">
<a name="22189574"></a>Neal JM, Mulroy MF, and Weinberg GL, “American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,” <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/22189574/pubmed" id="22189574" target="_blank">22189574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29065741">
<a name="29065741"></a>Parikh P, Sunesara I, Singh Multani S, Patterson B, Lutz E, Martin JN Jr. Intra-incisional liposomal bupivacaine and its impact on postcesarean analgesia: a retrospective study. <i>J Matern Fetal Neonatal Med</i>. 2019;32(6):966-970. doi:10.1080/14767058.2017.1397118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/29065741/pubmed" id="29065741" target="_blank">29065741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29889750">
<a name="29889750"></a>Prabhu M, Clapp MA, McQuaid-Hanson E, et al. Liposomal bupivacaine block at the time of cesarean delivery to decrease postoperative pain: a randomized controlled trial. <i>Obstet Gynecol</i>. 2018;132(1):70-78. doi:10.1097/AOG.0000000000002649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/liposomal-bupivacaine-pediatric-drug-information/abstract-text/29889750/pubmed" id="29889750" target="_blank">29889750</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131649 Version 26.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
